Vitrolife AB Fourth quarter and full year report, 2024: A strong finish to the year

GOTHENBURG, Sweden, Jan. 30, 2025 /PRNewswire/ -- Fourth quarter            

• Sales of SEK 959 (904) million, an increase of 6% in local currencies and 6% in SEK.           
• Sales per region, in local currencies was +10% in EMEA, +9% in Americas and -2% in APAC.           
• Sales per business area, in local currencies was +12% in Consumables, +9% in Technologies and 0% in Genetics.           
• Gross margin increased to 61.1% (56.9).           
• Operating income before depreciation and amortisation (EBITDA) increased to SEK 337 (294) million, giving an EBITDA margin of 35.1% (32.5).          
• Operating cash flow increased to SEK 268 million (171).           
• Net income was SEK 139 (-4,179) million, resulting in earnings per share before dilution of SEK 1.03 (-30.86) and after dilution of SEK 1.02 (-30.86).           
• Helena Wennerström was appointed acting CFO of Vitrolife AB (publ) effective 3 December 2024.

Full year            

• Sales of SEK 3,609 (3,512) million, an increase of 4% in local currencies and 3% in SEK.           
• Sales per region, in local currencies was +7% in EMEA, +1% in Americas and +5% in APAC.           
• Sales per business area, in local currencies was +10% in Consumables, +16% in Technologies and -5% in Genetics.           
• Gross margin increased to 59.3% (56.3).           
• Operating income before depreciation and amortisation (EBITDA) increased to SEK 1,225 (1,136) million, giving an EBITDA margin of 34.0% (32.3).           
• Operating cash flow increased to SEK 907 million (757).           
• Net income was SEK 514 (-3,851) million, resulting in earnings per share before dilution of SEK 3.79 (-28.44) and after dilution of SEK 3.78 (-28.44).

Dividend           

• The Board to propose to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share.

Gothenburg, January 30, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor,
CEO

The information was submitted for publication, through the agency of the contact persons set out above, at 30-01-2025 08:00 CET.

Contact: 
Helena Wennerström, acting CFO, phone: +4670 822 80 86

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/vitrolife-ab--publ-/r/fourth-quarter-and-full-year-report--2024--a-strong-finish-to-the-year,c4098077

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-fourth-quarter-and-full-year-report-2024-a-strong-finish-to-the-year-302364243.html

SOURCE Vitrolife AB (publ)